Stephen Ezell
Vice President at Information Technology and Innovation Foundation
Vice President, Global Innovation Policy at the Information Technology and Innovation Foundation @itifdc
Articles
-
1 week ago |
itif.org | Stephen Ezell
The Trump administration has appropriately placed emphasis on American manufacturing revitalization, and even touts as much as $5 trillion in new investment commitments. While this represents tremendous progress, these investments will only succeed if America demonstrates it possesses the manufacturing workforce and supply chains—often anchored in small- to medium-sized (SME) manufacturers with fewer than 500 workers—to make that vision a reality.
-
1 week ago |
itif.org | Stephen Ezell |Meghan Ostertag
KEY TAKEAWAYSThe United States has led the world in turning its universities into engines of innovation. From 1996 to 2020, academic technology transfer from U.S. universities resulted in 554,000 inventions disclosed, 141,000 U.S. patents granted, and 18,000 start-ups formed, in addition to the contribution of $1.9 trillion of U.S. gross industrial output.
-
2 weeks ago |
itif.org | Stephen Ezell
The "Creating Helpful Incentives to Produce Semiconductors" (CHIPS) Act has been a smashing success. Since it passed in August 2022, the legislation has helped stimulate $450 billion in U.S. semiconductor supply chain investments through more than 100 projects spread across 28 U.S. states, including 17 new fabs and eight new supply chain and advanced packaging facilities.
-
1 month ago |
itif.org | Stephen Ezell |Trelysa Long |Meghan Ostertag
KEY TAKEAWAYSA blanket 25 percent tariff on U.S. semiconductor imports would produce a 0.18 percent downturn in U.S. economic growth in the first year, and if sustained over 10 years, would result in a 0.76 percent slowdown in U.S. economic growth in the 10th year. A 10 percent tariff would result in 0.06 percent of U.S. gross domestic product (GDP) growth foregone in the first year and 0.20 percent in the 10th year.
-
1 month ago |
itif.org | Stephen Ezell
|May 15, 2025The Trump administration’s call for “Most Favored Nation” drug price controls will lead to less biopharmaceutical innovation and reduced U.S. drug industry competitiveness. However, the president’s willingness to use tariff negotiations to press other nations to pay their fair share for patented drugs is salutary. For decades, the United States has shouldered the lion’s share of global research and development in the life sciences.
Try JournoFinder For Free
Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.
Start Your 7-Day Free Trial →X (formerly Twitter)
- Followers
- 717
- Tweets
- 142
- DMs Open
- No
My latest ITIF report assesses "How Innovative Is China in Semiconductors?" - https://t.co/TH80BmmD1D
My latest report for ITIF explores "How Innovative Is China in Nuclear Power?" Much more than the United States is the unfortunate answer. https://t.co/MEvmcegm85
RT @ITIFdc: CAR-T therapy has shown remarkable success in treating blood cancers, but its high cost can make it unattainable. @Caring_Cross…